(NASDAQ: NBTX) Nanobiotix Sa's forecast annual revenue growth rate of 92.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.11%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.31%.
Nanobiotix Sa's revenue in 2025 is $11,950,588.On average, 7 Wall Street analysts forecast NBTX's revenue for 2025 to be $1,706,179,290, with the lowest NBTX revenue forecast at $1,087,254,564, and the highest NBTX revenue forecast at $2,740,518,226. On average, 7 Wall Street analysts forecast NBTX's revenue for 2026 to be $3,803,702,692, with the lowest NBTX revenue forecast at $709,079,064, and the highest NBTX revenue forecast at $7,756,456,697.
In 2027, NBTX is forecast to generate $3,669,894,166 in revenue, with the lowest revenue forecast at $567,263,251 and the highest revenue forecast at $5,520,686,996.